Arcus Biosciences Inc (RCUS)
17.10
+0.66
(+3.98%)
USD |
NYSE |
Dec 04, 16:00
17.10
0.00 (0.00%)
After-Hours: 20:00
Arcus Biosciences Debt to Equity Ratio: 0.0832 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.0832 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2019
0.0832
Maximum
Sep 2024
0.0042
Average
--
Median
Dec 2019
Debt to Equity Ratio Benchmarks
| Merck & Co Inc | 0.8568 |
| Regeneron Pharmaceuticals Inc | 0.0677 |
| NovaBay Pharmaceuticals Inc | 0.0476 |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.252B |
| Total Liabilities (Quarterly) | 687.00M |
| Shareholders Equity (Quarterly) | 565.00M |
| Current Ratio | 5.242 |
| Net Debt Paydown Yield | -0.67% |